About Farber > Mission & Overview > Director

Our Director and Our Research

Today's scientific advances, tomorrow's cures

The Farber Institute scientists are engaged in both basic and clinical research studies of beta amyloid, the sticky substance that builds up in the brain and blood vessels of patients with Alzheimer's and stroke. These studies have already translated into four clinical trials for Alzheimer’s patients.  The Parkinson's research group is pioneering methods for using stem cells to replace dying dopamine neurons. Researchers in the new Weinberg ALS Resesarch Unit are laying the groundwork for a completely new approach to treating Lou Gehrig’s disease. Major research initiatives are also underway in drug addiction, developmental neurobiology, and other neurodegenerative diseases like Huntington’s and Kennedy’s diseases.

With these as a cornerstone, the Farber Institute for Neuroscience is poised to take brain research at Jefferson into a new era, one in which the scientific advances of today are translated into the cures and treatments of tomorrow.

Click the links below to find out more about specific diseases and research.

Amyotrophic Lateral Sclerosis (ALS)

Alzheimer's

Parkinson's

Clinical

Other Movement Disorders

Continue

Go Back